Anna Avagyan

Anna Avagyan

Auto-generated profile, based on publicly available information

Anna Avagyan

Pediatric Cancer and Blood Disease Center Yeolan Hematology and Oncology Center Yerevan Armenia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2026 in Cancer
Verified
Journal Article
Open access
DDDaniel J. DeAngelo
Daniel J. DeAngelo
AAAnna Avagyan
Anna Avagyan
JAJeanine Alfaro
Jeanine Alfaro
VCValentino Conter
Valentino Conter
MLMaria L. de Martino Lee
Maria L. de Martino Lee
SHScott C. Howard
Scott C. Howard
Frontline blinatumomab combined with chemotherapy has resulted in improved outcomes in both pediatric and adult patients with acute lymphoblastic leukemia and is considered the new cornerstone of acute lymphoblastic leukemia treatment. The role of asparaginase in this new landscape of acute lymphoblastic leukemia treatment was extensively discussed by an expert panel of hemato‐oncologists to reach a consensus on the safety and efficacy of asparaginase in diverse settings with and without blinatumomab. Herein, the following consensus topics are presented: (1) optimal dosing of asparaginase and therapeutic drug monitoring; (2) prevention of asparaginase hypersensitivity reactions and inactivation; (3) integration of frontline blinatumomab, asparaginase, and antimetabolites; and (4) special issues of asparaginase formulations and adaptations for resource‐limited settings.